Sjögren's syndrome: mechanisms ofpathogenesis involve interaction of immune and neurosecretory systems

References

• Fox R. Pathogenesis of Sjogren's syndrome. In: R Rich, S Fleisher, B Kotzin, eds. Clinical Immunology: Principles and Practice. London: Harcourt Brace, 2001:89.1-89.32.
   Google Scholar
• Manthorpe R. New criteria for diagnosing Sjogren's syndrome: a step forward - or? Scand J Rheumatol 2001; 30 Suppl 115:14–22.
   Web of Science ®Google Scholar
• Vitali C, et al. Preliminary criteria for the classification of Sjogren's syndrome. Arthritis Rheum 1993;36:340–7.
   PubMed Web of Science ®Google Scholar
• Fox RI, Maruyama T. Pathogenesis and treatment of Sjogren's syndrome. Curr Opin Rheumatol 1997;9:393–9.
   PubMedGoogle Scholar
• Gipson IK, Inatomi T. Cellular origin of mucins of the ocular surface tear film. Adv Exp Med Biol 1998:438:221–7.
   PubMed Web of Science ®Google Scholar
• Danjo Y, et al. Alteration of mucin in human conjunctival epithelia in dry eye. Invest Ophthalmol Vis Sci 1998;39:2602–9.
   PubMed Web of Science ®Google Scholar
• Stern ME, et al. A unified theory of the role of the ocular surface in dry eye. Adv Exp Med Biol 1998;438:643–51.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, Solomon A, Stern ME. The diagnosis and management of dry eye: a twenty-five-year review. Cornea 2000:19:644–9.
   Google Scholar
• Nelson JD. Diagnosis of keratoconjunctivitis sicca. Int Ophthalmol Clin 1994;34:37–56.
   PubMedGoogle Scholar
• Daniels TaF, PC. Salivary and oral components of Sjogren's syndrome. Rheum Dis Clin North Am 1992;18:571–83.
   PubMed Web of Science ®Google Scholar
• Konttinen YT, et al. Topology of innervation of labial salivary glands by protein gene product 9.5 and synaptophysin immu-noreactive nerves in patients with Sjogren's syndrome. J Rheumatol 1992;19:30–7.
   Google Scholar
• Pedersen AM, et al. Innervation pattern and Ca2 + signalling in labial salivary glands of healthy individuals and patients with primary Sjogren's syndrome (pSS). J Oral Pathol Med 2000;29:97–109.
   PubMed Web of Science ®Google Scholar
• Steinfeld S, et al. Abnormal distribution of aquaporin-5 water channel protein in salivary glands from Sjogren's syndrome patients. Lab Invest 2001;81:143–8.
   PubMed Web of Science ®Google Scholar
• Ishikawa Y, Skowronski MT, Ishida H. Persistent increase in the amount of aquaporin-5 in the apical plasma membrane of rat parotid acinar cells induced by a muscarinic agonist SNI-2011. FEBS Lett 2000;477: 253–7.
   Google Scholar
• Fox R, Kang H, Pisa E. Cytokine transcription in salivary gland biopsies of SjOgren's syndrome. J. Immunol 1994;151:132–42.
   Google Scholar
• Main C, Blennerhassett P, Collins SM. Human recombinant interleukin 1 beta suppresses acetylcholine release from rat myenteric plexus. Gastroenterology 1993;104: 1648–54.
   Google Scholar
• Campbell IL. Neuropathogenic actions of cytokines assessed in transgenic mice. Int .1- Dev Neurosci 1995;13:275–84.
   PubMed Web of Science ®Google Scholar
• Chandross KJ, et al. Transforming growth factor-beta 1 and forskolin modulate gap junctional communication and cellular phenotype of cultured Schwann cells. J Neurosci 1995;15:262–73.
   PubMed Web of Science ®Google Scholar
• Lu G, et al. Tumor necrosis factor-alpha and interleukin-1 induce activation of MAP kinase and SAP kinase in human neuroma fibroblasts. Neurochem Int 1997;30:401–10.
   PubMed Web of Science ®Google Scholar
• Wu A.J, et al. Interferon-gamma-induced JAK2 and STAT1 signalling in a human salivary gland cell line. J Cell Physiol 1997;173: 110–4.
   Google Scholar
• Dai YS, et al. Evidence that M3 muscarinic receptors in rat parotid gland couple to two second messenger systems. Am J Cell Physiol 1991;261:C1063–73.
   PubMed Web of Science ®Google Scholar
• Wotta DR, et al. Ml, M3 and M5 muscarinic receptors stimulate mitogen-activated protein kinase. Pharmacology 1998;56:175–86.
   PubMed Web of Science ®Google Scholar
• Liu XB, et al. G-protein signaling abnormalities mediated by CD95 in salivary epithelial cells. Cell Death Differ 2000;7:1119–26.
   PubMed Web of Science ®Google Scholar
• Borda E, et al. Circulating antibodies against neonatal cardiac muscarinic acetylcholine receptor in patients with Sjogren's syndrome. Mol Cell Biochem 1996;163–164:335-41.
   Google Scholar
• Robinson CP, et al. A novel NOD-derived murine model of primary Sjogren's syndrome. Arthritis Rheum 1998;41:150–6.
   PubMed Web of Science ®Google Scholar
• Bacman S, et al. Autoantibodies against lacrimal gland M3 muscarinic acetylcholine receptors in patients with primary Sjogren's syndrome. Invest Ophthalmol Vis Sci 1998;39:151–6.
   PubMed Web of Science ®Google Scholar
• Waterman SA, Gordon TP, Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjogren's syndrome. Arthritis Rheum 2000;43:1647–54.
   Google Scholar
• Fox R. Treatment of Sjogren's syndrome. In: ME Weinblatt, ed. Therapy of Rheumatic Disease. Philadelphia: Saunders 1999:66–77.
   Google Scholar
• Lemp MA. The 1998 Castroviejo Lecture. New strategies in the treatment of dry-eye states. Cornea 1999;18:625–32.
   Google Scholar
• Balaram M, Schaumberg DA, Dana MR. Efficacy and toler-ability outcomes after punctal occlusion with silicone plugs in dry eye syndrome. Am J Ophthalmol 2001;131:30–6.
   Google Scholar
• Friedlaender MH, Fox RI. Punctal occlusion for the treatment of dry eye. Adv Exp Med Biol 1998;438:1017–20.
   PubMed Web of Science ®Google Scholar
• Marsh P, Pflugfelder SC. Topical nonpreserved methylpredni-solone therapy for keratoconjunctivitis sicca in Sjogren's syn-drome. Ophthalmology 1999;106:811–6.
   PubMed Web of Science ®Google Scholar
• Fox RI, et al. Beneficial effect of artificial tears made with autologous serum in patients with keratconjunctivitis Sicca. Arthritis Rheum 1984; 27:459–61.
   PubMed Web of Science ®Google Scholar
• Tsubota K, et al. Treatment of dry eye by autologous serum application in Sjogren's syndrome. Br J Ophthalmol 1999;83:390–5.
   PubMed Web of Science ®Google Scholar
• Sall K, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000;107: 631–9.
   Google Scholar
• Daniels TE, Wu AJ. Xerostomia-clinical evaluation and treat-ment in general practice. J Can Dent Assoc 2000;28:933–41.
   Google Scholar
• Fox RI. Sjogren's syndrome: current therapies remain inad-equate for a common disease. Expert Opin Investig Drugs 2000;9:2007–16.
   PubMed Web of Science ®Google Scholar
• Ferraccioli G, et al. Interferon alpha-1 increases lacrimal and salivary function in Sjogren's syndrome patients. Preliminary results of an open pilot trial versus hydroxychloroquine. Clin Exp Rheumatol 1996;14:367–71.
   Google Scholar
• Ship JA, et al. Treatment of primary Sjogren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group. J Interferon Cytokine Res 1999;19:943–51.
   PubMed Web of Science ®Google Scholar
• Shiozawa S, et al. A preliminary study on the interferon-alpha treatment for xerostomia of Sjogren's syndrome. Br J Rheumatol 1993;32:52–4.
   PubMedGoogle Scholar
• Steinfeld SD, et al. Infliximab in patients with primary SjOgren's syndrome: a pilot study. Arthritis Rheum 2001;44:2371–5.
   PubMed Web of Science ®Google Scholar
• Charles PJ, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treat-ment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000;43:2383–90.
   PubMed Web of Science ®Google Scholar
• Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther 1999; 13 Suppl 4:16–22; discus-sion 38.
   Google Scholar
• Kaswan R. Characteristics of a canine model of KCS: effective treatment with topical cyclosporine. Adv Exp Med Biol 1994;350:583–94.
   PubMedGoogle Scholar
• Tsubota K, et al. Use of topical cyclosporin A in a primary Sjogren's syndrome mouse model. Invest Ophthalmol Vis Sci 1998;39:1551–9.
   PubMed Web of Science ®Google Scholar
• Hingorani M, et al. The immunomodulatory effect of topical cyclosporin A in atopic keratoconjunctivitis. Invest Ophthalmol Vis Sci 1999;40:392–9.
   PubMed Web of Science ®Google Scholar
• Hingorani M. et al. A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratocon-junctivitis. Ophthalmology 1998;105:1715–20.
   PubMed Web of Science ®Google Scholar
• Kunert KS, et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol 2000;118:1489–96.
   PubMed Web of Science ®Google Scholar
• Turner K, et al. Interleukin-6 levels in the conjunctival epithe-lium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea 2000;19:492–6.
   PubMed Web of Science ®Google Scholar
• Alpert S, et al. Expression of granzyme A in salivary gland biopsies from patients with primary Sjogren's syndrome. Arthritis Rheum 1994;37:1046–54.
   PubMed Web of Science ®Google Scholar
• Ogawa N, et al. Lymphocyte apoptosis and apoptosis-associated gene expression in Sjogren's syndrome. Arthritis Rheum 1996;39:1875–86.
   PubMed Web of Science ®Google Scholar
• Bacman S, et al. Circulating antibodies against rat parotid gland M3 muscarinic receptors in primary Sjogren's syndrome. Clin Exp Immunol 1996;104:454–9.
   PubMed Web of Science ®Google Scholar
• Robinson CP, et al. Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjogren's syndrome. Proc Natl Acad Sci U S A 1998;95:7538–43.
   PubMed Web of Science ®Google Scholar
• Konttinen YT, et al. Matrix metalloproteinase (MMP)-9 type IV collagenase/gelatinase implicated in the pathogenesis of Sjogren's syndrome. Matrix Biol 1998;17:335–47.
   PubMed Web of Science ®Google Scholar
• Yamachika S, et al. Excessive synthesis of matrix metallo-proteinases in exocrine tissues of NOD mouse models for Sjogren's syndrome. J Rheumatol 1998;25:2371–80.
   PubMed Web of Science ®Google Scholar
• Tominaga M. et al. Expression of metalloproteinase-2 (gelatin-ase A) in labial salivary glands of patients with Sjogren's syndrome with HTLV-I infection. Clin Exp Rheumatol 1999;17:463–6.
   PubMed Web of Science ®Google Scholar
• Johnson EO, Skopouli FN, Moutsopoulos HM. Neuroendocrine manifestations in Sjogren's syndrome. Rheum Dis Clin North Am 2000; 26:927–49.
   PubMed Web of Science ®Google Scholar
• Robinson CP, et al. Genetically programmed development of salivary gland abnormalities in the NOD (nonobese diabetic)-scid mouse in the absence of detectable lymphocytic infiltra-tion: a potential trigger for sialoadenitis of NOD mice. Clin Immunol Immunopathol 1996;79:50–9.
   PubMedGoogle Scholar
• Brayer J, et al. Alleles from chromosomes 1 and 3 of NOD mice combine to influence Sjogren's syndrome-like auto-immune exocrinopathy. J Rheumatol 2000;27:1896–904.
   PubMed Web of Science ®Google Scholar
• Humphreys-Beher MG, et al. Salivary gland changes in the NOD mouse model for Sjogren's syndrome: is there a non-immune genetic trigger? Eur J Morphol 1998;36 Suppl 247–51.
   Google Scholar
• Haneji N, et al. Identification of alpha-fodrin as a candidate autoantigen in primary SjOgren's syndrome. Science 1997;276:604–7.
   PubMed Web of Science ®Google Scholar
• Morinobu A, et al. Association of the glutathione S-transferase M1 homozygous null genotype with susceptibility to Sjogren's syndrome in Japanese individuals. Arthritis Rheum 1999; 42: 2612–5.
   PubMed Web of Science ®Google Scholar
• Toda I, Wickham LA, Sullivan DA. Gender and androgen treatment influence the expression of proto-oncogenes and apoptotic factors in lacrimal and salivary tissues of MRL/lpr mice. Clin Immunol Immunopathol 1998;86:59–71.
   Google Scholar
• Komaki S, et al. The polymorphic 43Thr bc1-2 protein confers relative resistance to autoimmunity: an analytical evaluation. Hum Genet 1998;103:435–40.
   PubMed Web of Science ®Google Scholar
• Griffiths DJ, et al. A novel exogenous retrovirus sequence identified in humans. J Virol 1997; 71:2866–72.
   PubMed Web of Science ®Google Scholar
• Li JM, et al. The expression of human endogenous retrovirus-3 in fetal cardiac tissue and antibodies in congenital heart block. Clin Exp Immunol 1996;104:388–93.
   PubMed Web of Science ®Google Scholar
• Talal N, Flescher E, Dang H. Evidence for possible retroviral involvement in autoimmune diseases. Ann Allergy 1992:69:221–4.
   Google Scholar
• Tornwall J, et al. T cell attractant chemokine expression initi-ates lacrimal gland destruction in nonobese diabetic mice. Lab Invest 1999;79:1719–26.
   PubMed Web of Science ®Google Scholar
• Jalkanen S, et al. A distinct endothelial cell recognition system controlling lymphocyte traffic into inflamed synovium. Science 1986;233:556–8.
   PubMed Web of Science ®Google Scholar
• Salmi M, Jalkanen S. Different forms of human vascular adhesion protein-1 (YAP-1) in blood vessels in vivo and in cultured endothelial cells: implications for lymphocyte-endothelial cell adhesion models. Eur J Immunol 1995;25:2803–12.
   PubMed Web of Science ®Google Scholar
• Oxholm P, Daniels TE, Bendtzen K. Cytokine expression in labial salivary glands from patients with primary Sjogren's syndrome. Auto immunity 1992;12:185–91.
   Google Scholar
• Boumba D, Skopouli F, Moutsopoulos H. Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjogren's syndrome. Brit J Rheum 1995;34:326–33.
   Google Scholar
• Ohyama Y, et al. Cytokine messenger RNA expression in the labial salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 1996;39:1376–84.
   PubMed Web of Science ®Google Scholar
• Kong L, et al. Fas and Fas ligand expression in the salivary glands of patients with primary Sjogren's syndrome. Arthritis Rheum 1997;40:87–97.
   PubMed Web of Science ®Google Scholar
• Cuello C, et al. Chemokine expression and leucocyte infiltra-tion in Sjogren's syndrome. Br J Rheumatol 1998;37:779–83.
   PubMedGoogle Scholar
• Horsfall AC, Li JM, Maini RN. Placental and fetal cardiac laminin are targets for cross-reacting autoantibodies from mothers of children with congenital heart block. J Autoimmun 1996;9:561–8.
   Google Scholar
• McCauliffe DP, et al. Autoimmune sera react with multiple epitopes on recombinant 52 and 60 kDa Ro(SSA) proteins. J Rheumatol 1994;21:1073–80.
   PubMed Web of Science ®Google Scholar
• Wu AJ, et al. Modulation of MMP-2 (gelatinase A) and MMP-9 (gelatinase B) by interferon-gamma in a human salivary gland cell line. J Cell Physiol 1997;171:117–24.
   PubMed Web of Science ®Google Scholar
• Ohlsson M, et al. Fas-induced apoptosis is a rare event in Sjogren's syndrome. Lab Invest 2001; 81:95–105.
   PubMed Web of Science ®Google Scholar
• Konttinen YT, et al. Role of nitric oxide in Sjogren's syndrome. Arthritis Rheum 1997;40:875–83.
   PubMed Web of Science ®Google Scholar
• Yamamoto H, et al. Alterations in the secretory response of non-obese diabetic (NOD) mice to muscarinic receptor stimu-lation. Clin Immunol Immunopathol 1996;78:245–55.
   PubMedGoogle Scholar
• Fox RI, Tornwall J, Michelson P. Current issues in the diagnosis and treatment of Sjogren's syndrome. Curr Opin Rheumatol 1999;11:364–71.
   PubMedGoogle Scholar
• Daniels TE. Evaluation, differential diagnosis, and treatment of xerostomia. J Rheumatol 2000;. 27 Suppl 61:6–10.
   Google Scholar
• Vivino FB, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 1999;159:174–81.
   PubMed Web of Science ®Google Scholar
• Vivino FB. The treatment of Sjogren's syndrome patients with pilocarpine-tablets. Scand J Rheumatol 2001:30 Suppl 115: 1–13.
   PubMed Web of Science ®Google Scholar
• Iwabuchi Y, Masuhara T. Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjogren's syndrome. Gen Pharmacol 1994;25:123–9.
   PubMedGoogle Scholar
• Fox PC, Mandel ID. Effects of pilocarpine on salivary flow in patients with Sjogren's syndrome Oral Surg Oral Med Oral Pathol 1992;74:315–8.
   PubMedGoogle Scholar
• Rhodus NL. Oral pilocarpine HC1 stimulates labial (minor) salivary gland flow in patients with Sjogren's syndrome. Oral Dis 1997;3:93–8.
   PubMedGoogle Scholar
• Iga Y, et al.. ( ±)-cis-2-methylspiro [1,3-oxathiolane-5,3'-quinu-clidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: the role of muscarinic acetylcholine receptors. Jpn J Pharmacol 1998;78:373–80.
   PubMedGoogle Scholar
• Fox R. Treatment of SjOgren's syndrome. In: MaW Weinblatt, ed. Drug Therapy of Rheumatic Disease. Philadelphia: Saunders 1995: 68–77.
   Google Scholar
• Fox R. Antimalarial medications for treatment of autoimmune disorders. In: W. Koopman, ed. Arthritis and Allied Conditions. Baltimore: Williams and Wilkens, 1996:671–8.
   Google Scholar
• Fox RI, et al. Treatment of primary Sjogren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 1996;5 Suppl 1:S31–6.
   PubMed Web of Science ®Google Scholar
• Skopouli FN, et al. Methotrexate in primary Sjogren's syn-drome. Clin Exp Rheumatol 1996;14: 555–8.
   PubMed Web of Science ®Google Scholar
• Drosos AA, et al. Cyclosporin A (CyA) in primary Sjogren's syndrome: a double blind study. Ann Rheum Dis 1986;45:732–5.
   PubMed Web of Science ®Google Scholar
• Linardaki G, Moutsopoulos HM. The uncertain role of immunosuppressive agents in Sjogren's syndrome. Cleve Clin J Med 1997;64:523–6.
   PubMed Web of Science ®Google Scholar
• Bartlett RR, et al. Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis. Transplant Proc 1996;28:3074–8.
   PubMed Web of Science ®Google Scholar
• Fox R., et al. sTNFbp prevents development of lymphoid infiltrates in the NOD mouse, a model for human Sjogren's syndrome. Arthritis Rheum 1999;41 Supplement:5181.
   Google Scholar
• Jonsson R, Haga HJ, Gordon TP. Current concepts on diagnosis, autoantibodies and therapy in Sjogren's syndrome. Scand J Rheumatol 2000:29:341–8.
   Google Scholar